Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases

被引:18
作者
Baize, Nathalie
Gerard, Beatrice
Bleiberg, Harry
Caroli-Bosc, Francois
Berthier, Frederic
Legendre, Hughes
Pector, Jean-Claude
Hendlisz, Alain
机构
[1] Hop Larchet 2, Federat Malad Appareil Digest, F-06202 Nice 2, France
[2] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
来源
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE | 2006年 / 30卷 / 12期
关键词
D O I
10.1016/S0399-8320(06)73553-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives - To evaluate long-term survival of patients resected for primarily unresectable colorectal liver metastases downstaged by systemic chemotherapy. Methods - Among a group of 82 patients with advanced colorectal cancer, 39 had unresectable liver metastases. After treatment with systemic 3-weekly 5FU/folinic acid/oxaliplatin chemotherapy, the outcome of 11 patients made resectable thanks to chemotherapy was compared to that of 28 patients who were not. Criteria for non-resectability consisted of diffuse bilobar invasion with inability to achieve complete resection, unilobar or bilobar invasion plus vascular extension (invasion of inferior vena cava or 2 suprahepatic veins plus continuity with the 3(rd)) or involvment of hepatic pedicle. Before and after surgery, CT scan evaluation was performed every 2 months. Progression free survival was defined as the time between starting chemotherapy and recurrence of the disease. We used Kaplan-Meier survival curves and log-rank test for comparisons, P values were two-sided and considered significant if < 0.05. Results - Progression free survival times were 14 and 6 months, median overall survival were 60 and 18.5 months, respectively, in favour of secondary resected subjects. Conclusion - Considering the magnitude of the survival benefit, one may question the need and feasibility for trials to assess more formally the impact of surgery in that setting.
引用
收藏
页码:1349 / 1353
页数:5
相关论文
共 31 条
[1]   Tumor progression while on chemotherapy - A contraindication to liver resection for multiple colorectal metastases? [J].
Adam, R ;
Pascal, G ;
Castaing, D ;
Azoulay, D ;
Delvart, V ;
Paule, B ;
Levi, F ;
Bismuth, H .
ANNALS OF SURGERY, 2004, 240 (06) :1052-1064
[2]   Regional treatment of metastasis: surgery of colorectal liver metastases [J].
Adam, R ;
Vinet, E .
ANNALS OF ONCOLOGY, 2004, 15 :103-106
[3]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[4]  
Adam R, 2001, ANN SURG ONCOL, V8, P347
[5]   Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors [J].
Adam, R ;
Laurent, A ;
Azoulay, D ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 232 (06) :777-784
[6]   Liver resection for colorectal metastases - The third hepatectomy [J].
Adam, R ;
Pascal, G ;
Azoulay, D ;
Tanaka, K ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2003, 238 (06) :871-883
[7]   Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].
Alberts, SR ;
Horvath, WL ;
Stcrnfeld, WC ;
Goldberg, RM ;
Mahoney, MR ;
Dakhil, SR ;
Levitt, R ;
Rowland, K ;
Nair, S ;
Sargent, DJ ;
Donohue, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249
[8]   Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization [J].
Azoulay, D ;
Castaing, D ;
Smail, A ;
Adam, R ;
Cailliez, V ;
Laurent, A ;
Lemoine, A ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 231 (04) :480-486
[9]   Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J].
Bismuth, H ;
Adam, R ;
Levi, F ;
Farabos, C ;
Waechter, F ;
Castaing, D ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1996, 224 (04) :509-520
[10]  
BOZZETTI F, 1999, ANN ONCOL, V10, P663